IDO1 antibody [GT273]
GTX634652
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetIDO1
Overview
- SupplierGeneTex
 - Product NameIDO1 antibody [GT273]
 - Delivery Days Customer9
 - Application Supplier NoteWB: 1:1000-1:10000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
 - ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
 - CertificationResearch Use Only
 - ClonalityMonoclonal
 - Clone IDGT273
 - Concentration1 mg/ml
 - ConjugateUnconjugated
 - Gene ID3620
 - Target nameIDO1
 - Target descriptionindoleamine 2,3-dioxygenase 1
 - Target synonymsIDO; IDO-1; INDO; indolamine 2,3 dioxygenase; indole 2,3-dioxygenase; indoleamine 2,3-dioxygenase 1; indoleamine-pyrrole 2,3-dioxygenase
 - HostMouse
 - IsotypeIgG2a
 - Protein IDP14902
 - Protein NameIndoleamine 2,3-dioxygenase 1
 - Scientific DescriptionThis gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.[provided by RefSeq, Feb 2011]
 - Storage Instruction-20°C or -80°C,2°C to 8°C
 - UNSPSC12352203
 
References
- TNFalpha and IFNgamma rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property.Read more
 - Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival. Sorrentino C et al., 2021, Front ImmunolRead more
 







